Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon D Roger

Showing results (21-30 of 71) with videos related to

Pageof 8
Sort By:
International Urology and Nephrology|August 29, 2013
A randomised single-blind study to improve health-related quality of life by treating anaemia of chronic kidney disease with Aranesp® (darbepoetin alfa) in older people: STIMULATESimon D Roger, Sarbjit V Jassal, Michael C Woodward, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 9, 2010
A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patientsWajeh Y Qunibi, Carlos Martinez, Mark Smith, et al.
Clinical Journal of the American Society of Nephrology : CJASN|December 18, 2012
Peginesatide for maintenance treatment of anemia in hemodialysis and nondialysis patients previously treated with darbepoetin alfaSteven Fishbane, Simon D Roger, Edouard Martin, et al.
Clinical Nephrology|December 22, 2011
Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-α (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind studyMarianne Haag-Weber, Kai-Uwe Eckardt, Walter H Hörl, et al.
Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis|March 4, 2014
Peginesatide to Manage Anemia in Chronic Kidney Disease Patients on Peritoneal DialysisRaja Zabaneh, Simon D Roger, Mohamed El-Shahawy, et al.
Australian Family Physician|September 12, 2013
ACEIs for cardiovascular risk reduction--have we taken our eye off the ball?Andrew Sindone, Jonathan Erlich, Vlado Perkovic, et al.
American Journal of Nephrology|October 29, 2019
Efficacy and Safety of Sodium Zirconium Cyclosilicate for Treatment of Hyperkalemia: An 11-Month Open-Label Extension of HARMONIZESimon D Roger, Bruce S Spinowitz, Edgar V Lerma, et al.
The Medical Journal of Australia|September 27, 2006
Implementing iron management clinical practice guidelines in patients with chronic kidney disease having dialysisMichelle J Irving, Jonathan C Craig, Martin Gallagher, et al.
Nephrology (Carlton, Vic.)|February 11, 2014
Darbepoetin alfa once monthly corrects anaemia in patients with chronic kidney disease not on dialysisSimon D Roger, Elena Kolmakova, Maple Fung, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|April 25, 2006
Effect of early correction of anemia on the progression of CKDJérôme Rossert, Adeera Levin, Simon D Roger, et al.
Pageof 8

Showing results (21-30 of 71) with videos related to

Sort By:
Pageof 8
International Urology and Nephrology|August 29, 2013
A randomised single-blind study to improve health-related quality of life by treating anaemia of chronic kidney disease with Aranesp® (darbepoetin alfa) in older people: STIMULATESimon D Roger, Sarbjit V Jassal, Michael C Woodward, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 9, 2010
A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patientsWajeh Y Qunibi, Carlos Martinez, Mark Smith, et al.
Clinical Journal of the American Society of Nephrology : CJASN|December 18, 2012
Peginesatide for maintenance treatment of anemia in hemodialysis and nondialysis patients previously treated with darbepoetin alfaSteven Fishbane, Simon D Roger, Edouard Martin, et al.
Clinical Nephrology|December 22, 2011
Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-α (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind studyMarianne Haag-Weber, Kai-Uwe Eckardt, Walter H Hörl, et al.
Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis|March 4, 2014
Peginesatide to Manage Anemia in Chronic Kidney Disease Patients on Peritoneal DialysisRaja Zabaneh, Simon D Roger, Mohamed El-Shahawy, et al.
Australian Family Physician|September 12, 2013
ACEIs for cardiovascular risk reduction--have we taken our eye off the ball?Andrew Sindone, Jonathan Erlich, Vlado Perkovic, et al.
American Journal of Nephrology|October 29, 2019
Efficacy and Safety of Sodium Zirconium Cyclosilicate for Treatment of Hyperkalemia: An 11-Month Open-Label Extension of HARMONIZESimon D Roger, Bruce S Spinowitz, Edgar V Lerma, et al.
The Medical Journal of Australia|September 27, 2006
Implementing iron management clinical practice guidelines in patients with chronic kidney disease having dialysisMichelle J Irving, Jonathan C Craig, Martin Gallagher, et al.
Nephrology (Carlton, Vic.)|February 11, 2014
Darbepoetin alfa once monthly corrects anaemia in patients with chronic kidney disease not on dialysisSimon D Roger, Elena Kolmakova, Maple Fung, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|April 25, 2006
Effect of early correction of anemia on the progression of CKDJérôme Rossert, Adeera Levin, Simon D Roger, et al.
Pageof 8